1-18 of 18
durvalumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Shadi Swaidani, MD PhD, Joanna Roopkumar, MBBS, MPH, Young Jun-Shim, PhD, Cathy Charles, Slato Paul, Suman Kundu, MBA, Pauline Funchain, MD, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, PhD, Alok A Khorana, MD, Keith R McCrae, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3648.
https://doi.org/10.1182/blood-2019-130911
Published: 2019
Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman
Journal: Blood
Blood (2019) 134 (Supplement_1): 829.
https://doi.org/10.1182/blood-2019-122896
Published: 2019
Journal Articles

Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression and Gene Expression Profile

Christiane Querfeld, MD PhD, Xiwei Wu, PhD, Tracy Stiller, MS, Joycelynne Palmer, PhD, James F Sanchez, PhD, Xochiquetzal Martinez, MD, Steven Rosen, MD, Jasmine Zain, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4024.
https://doi.org/10.1182/blood-2019-126358
Published: 2019
Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor
Journal: Blood
Blood (2019) 134 (Supplement_1): 5328.
https://doi.org/10.1182/blood-2019-122635
Published: 2019
Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong
Journal: Blood
Blood (2019) 134 (Supplement_1): 5332.
https://doi.org/10.1182/blood-2019-127858
Published: 2019
Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, MD PhD, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, MD PhD, Simon Rule, Javier Munoz, MD, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood
Blood (2019) 134 (Supplement_1): 5320.
https://doi.org/10.1182/blood-2019-124102
Published: 2019
Journal Articles

Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Craig H. Moskowitz, Mariana Bastos-Oreiro, MD PhD, David Ungar, MD, Ilva Dautaj, Matko Kalac, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2807.
https://doi.org/10.1182/blood-2019-128036
Published: 2019
Journal Articles

Eliciting Anti-Tumor T Cell Immunity in Chronic Lymphocytic Leukemia (CLL) with PD-L1/PD-1 Blockade Is Enhanced By Avadomide Immunotherapy through the Triggering of Immunogenic Interferon Signaling

Nikolaos Ioannou, PhD MSc, BSc, Patrick R. Hagner, PhD, Fadi Towfic, PhD, Anita K. Gandhi, PhD, Kostas Stamatopoulos, MD PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Anna Vardi, MD PhD, Alan G. Ramsay, BSc,MSc,PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 237.
https://doi.org/10.1182/blood-2018-99-111605
Published: 2018
Journal Articles

Venous Thromboembolism in Cancer Patients Receiving Immunotherapy

Joanna Roopkumar, MBBS, MPH, Ann S. Kim, BA, Thapa Bicky, MD, Brian P. Hobbs, PhD, Alok A. Khorana, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2510.
https://doi.org/10.1182/blood-2018-99-116439
Published: 2018
Journal Articles

Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Frances Seymour, MRCP, BSc, MBBS, Mary H Young, PhD, Mark Tometsko, BSc, Jamie Cavenagh, MD PhD, Ethan G. Thompson, PhD, Elizabeth Whalen, PhD, Sam A Danziger, Alison Fitch, Brian A. Fox, PhD, Andrew Dervan, Teri Foy, PhD, Katie Newhall, PhD, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 3296.
https://doi.org/10.1182/blood-2018-99-114453
Published: 2018
Journal Articles

Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

Mariko Ishibashi, PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Hiroshi Handa, MD PhD, Koiti Inokuchi, MD PhD, Hidemi Takahashi, MD PhD, Hideto Tamura, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4439.
https://doi.org/10.1182/blood-2018-99-112322
Published: 2018
Journal Articles

Immune-Mediated Hematologic Complications of Checkpoint Inhibitors: A Review of the Literature

Omar Sallam, MD, Irbaz Bin Riaz, MD MMSc, Ronald S. Go, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5883.
https://doi.org/10.1182/blood-2018-99-113341
Published: 2018
Journal Articles

The New Landscape of Checkpoint Inhibitors in China

Chien-Shing Chen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5855.
https://doi.org/10.1182/blood-2018-99-111666
Published: 2018
Journal Articles

Phase 1/2 Trial of Durvalumab and Lenalidomide in Patients with Cutaneous T Cell Lymphoma (CTCL): Preliminary Results of Phase I Results and Correlative Studies

Christiane Querfeld, MD PhD, Jasmine M. Zain, MD, Devin L. Wakefield, PhD, Tijana Jovanovic-Talisman, PhD, Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Joycelynne Palmer, Steven T Rosen
Journal: Blood
Blood (2018) 132 (Supplement 1): 2931.
https://doi.org/10.1182/blood-2018-99-114001
Published: 2018
Journal Articles

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Stefan J. Müller, PharmD, Dagmar Wider, Andreas R. Thomsen, MD, Marie Follo, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, Sandra M. Dold, MSc, Julia Felthaus, Johanna Senger, PhD, Julia Schüler, DVM, Justus Duyster, Abdel Kareem Azab, PhD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt
Journal: Blood
Blood (2017) 130 (Supplement 1): 1793.
https://doi.org/10.1182/blood.V130.Suppl_1.1793.1793
Published: 2017
Journal Articles

PD-L1 Is Regulated By Interferon Gamma and Interleukin 6 through STAT1 and STAT3 Signaling in Cutaneous T-Cell Lymphoma

Sung Hee Kil, PhD, Renee Estephan, BS, James Sanchez, PhD, Jasmine M. Zain, MD, Marshall E. Kadin, MD, James W. Young, MD, Steven T. Rosen, MD, Christiane Querfeld, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1458.
https://doi.org/10.1182/blood.V130.Suppl_1.1458.1458
Published: 2017
Journal Articles

The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort

Zack M. Breckenridge, BSc, Victor Jimenez-Zepeda, MD, Nizar J. Bahlis, MD, Paola Neri, MD, Irwindeep Sandhu, MDFRCPC, Michael P. Chu, MD, Ismail Ismail, Jason Tay, MD FRCPC, Peter Duggan, MD FRCPC, Andrew Belch, Joanne D. Hewitt, NP, PhD, Linda M. Pilarski, PhD, Tatiana Nikitina, Christopher P. Venner
Journal: Blood
Blood (2017) 130 (Supplement 1): 1859.
https://doi.org/10.1182/blood.V130.Suppl_1.1859.1859
Published: 2017
Journal Articles

Preclinical Analyses Support Clinical Investigation of Combined PD-L1 Blockade and Anti-CD19 CAR T Cell Therapy for the Treatment of NHL

Ryan P Larson, PhD, Michael Ports, PhD, Heidi Jessup, Guadalupe Manriquez, MD, Carl Hay, Ross Stewart, PhD, Marlon Rebelatto, DVM, PhD, Robert Hollingsworth, PhD, Valerie Odegard, PhD
Journal: Blood
Blood (2015) 126 (23): 5430.
https://doi.org/10.1182/blood.V126.23.5430.5430
Published: 2015